Compare Quest Diagnostics Inc (DGX) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tyson Foods, Inc. — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Tyson Foods, Inc. trades at $57.48 (market cap $20.24B). The key difference: Quest Diagnostics Inc and Tyson Foods, Inc. are close in size by market cap, and Tyson Foods, Inc. pays the higher dividend (3.55%). Which is the better fit depends on your goals.
| DGX | TSN | |
|---|---|---|
Market Cap | $22.80B | $20.24B |
Sector | Health | Consumer Staples |
52-Week High | $216.02 | $68.75 |
52-Week Low | $166.42 | $50.72 |
Enterprise Value | $28.82B | $27.82B |
Dividend Yield | 1.67% | 3.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Tyson Foods (TSN) trades at $57.92, up 0.16% on the day, with a bearish technical signal but mixed earnings performance including a Q1 2026 beat. The company shows modest revenue growth to $54.44 billion in 2025, though net margins are thin at 0.81%. Recent news highlights innovation in prepared foods and new leadership appointments, while analyst consensus leans bullish with a $68.80 price target.
The stock presents a value opportunity with low P/S and P/B ratios, but faces risks from volatile earnings, high debt, and competitive pressures. Upside depends on execution in value-added segments and cost management, with the current price offering a 19% discount to the consensus target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
